BioVie completes enrollment in Long COVID treatment trial

BioVie completed enrollment in its ADDRESS-LC Phase 2 trial for bezisterim in Long COVID, with about 200 participants and topline data expected in late summer 2026. The study is fully funded by a $13.13 million U.S. Department of War grant, reducing financing risk, while the company also reported ongoing progress in Parkinson’s disease with SUNRISE-PD topline results due in Q3 2026. The news is positive for development execution, but near-term market impact should be limited given the long timeline to readout.

Analysis

The near-term trade is not the enrollment milestone itself; it is the optionality reset. With funding de-risked by a third party and a binary readout pushed into late summer 2026, BIVI effectively becomes a low-float catalyst vehicle whose equity value will be driven less by current operations than by implied probability of a clean phase-2 signal. In microcaps, that usually compresses the downside on “survival” headlines while magnifying upside into data because incremental demand can overwhelm limited liquidity.

The second-order winner, if the data are positive, is not just BioVie but the broader thesis that CNS-penetrant repurposed assets can still generate meaningful valuation support in diseases with no approved therapies. That would increase scrutiny on competing Long COVID programs and, more importantly, force Parkinson’s/Alzheimer’s investors to re-rate bezisterim as a platform asset rather than a single-indication shot. The reverse is also true: if cognitive endpoints miss while fatigue/symptom scores improve, the market may discount the whole program despite a potentially salvageable subpopulation signal.

The key risk is time decay. Two top-line events in 2026 means the stock likely trades as a sentiment instrument for months, not a fundamentals story, and any broad biotech risk-off or small-cap liquidity crunch can overwhelm trial progress. Another hidden risk is endpoint complexity: cognitive batteries are noisy and placebo effects in Long COVID are high, so even a biologically active drug can fail to clear statistical significance if enrollment heterogeneity is large.

Consensus may be underappreciating that the grant-backed structure lowers dilution risk but also caps the urgency premium until data. That argues for buying weakness rather than chasing momentum, because the real repricing window is the 4-6 weeks before readout when positioning can tighten and borrow can become meaningful. If the market starts to treat this as a multi-program CNS platform, the stock can re-rate well above fair value; if not, it remains a short-duration event trade with a high chance of mean reversion.

Key Decisions for Investors

• Maintain a small tactical long BIVI only on pullbacks, with a 3-6 month horizon; target a 20-30% upside rerating into 2026 catalysts, but cap position size given binary trial risk and microcap liquidity.
• If forced to express the view before data, prefer a call spread in BIVI over common stock to limit capital at risk while preserving convexity into late-summer 2026 topline.
• Pair trade: long BIVI / short a basket of less-differentiated small-cap CNS biotech names into the catalyst window; thesis is that a clean signal should disproportionately reward platform assets with funded, de-risked trials.
• Do not chase after sharp one-day rallies; use >15% momentum spikes as opportunities to fade into strength unless confirmed by unusually high volume, because this name is likely to suffer liquidity-driven retracements.
• Set a pre-readout risk trigger 6-8 weeks before topline; if data visibility remains poor or broader biotech risk appetite deteriorates, reduce exposure by at least half to avoid time-decay and gap risk.